BioRestorative Therapies Reports 2024 Financial Results and Provides Business Update

Core Viewpoint - BioRestorative Therapies, Inc. reported a transformative year in 2024 with significant financial improvements and advancements in clinical programs, focusing on executing its growth strategy moving forward [2] Development - In November 2024, BioRestorative received a provisional license from the New York State Department of Health for processing allogeneic donor tissue material, expanding its capabilities beyond autologous donors [2] - The company presented positive data from its Phase 2 clinical trial of BRTX-100 for chronic lumbar disc disease at the 2025 Orthopaedic Research Society Annual Meeting, showing no serious adverse events and promising preliminary results [7] - The FDA granted Fast Track designation to the BRTX-100 program, which may expedite its review process for treatment of chronic lumbar disc disease [7] - The FDA also cleared the Investigational New Drug application for BRTX-100 for chronic cervical discogenic pain, broadening its clinical pipeline [7] Commercial - BioRestorative generated $300,000 in revenue from its BioCosmeceuticals segment in 2024 [5] Financial Results - Total revenue for 2024 was $401,000, a 175% increase from $146,000 in 2023 [8] - The company's loss from operations improved by 24% to $11.6 million in 2024, compared to a loss of $15.2 million in 2023 [8] - The net loss for 2024 was $9.0 million, or $1.16 per share, a 14% improvement from a net loss of $10.4 million, or $2.47 per share, in 2023 [8] - Cash used in operating activities was $8.2 million, and the company ended the year with $10.7 million in cash and no outstanding debt [8][9]